Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection.
The clinical effects of inhaled ipratropium bromide were studied in 14 non-smoking patients with persistent post-viral infective cough employing a controlled double-blind, cross-over trial. Patients were selected if they demonstrated no apparent underlying cause for their persistent cough after appropriate radiological and respiratory function tests including methacholine reactivity and bronchoscopic examination. Inhaled ipratropium bromide (320 micrograms day-1) produced significantly less day and night time cough (P < 0.05) with overall clinical improvement in 12 cases, five of whom had total resolution of their cough. We conclude that ipratropium bromide is an effective treatment in non-smoking adults with protracted cough following clinical upper respiratory tract infection.
Holmes
P W
PW
Department of Respiratory Medicine, Heidelberg Repatriation Hospital, Melbourne, Victoria, Australia.
Barter
C E
CE
Pierce
R J
RJ
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003371:Cough / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000150:complications*; D014797:Vital Capacity / Q000187:drug effects
D009241:Ipratropium